Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose isotretinoin for persistent low grade adult acne
ACTRN12612000062820Phase 3Completed
- Sponsor
- Douglas Pharmaceuticals
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of isotretinoin in acne vulgaris (2 arms), sponsored by Douglas Pharmaceuticals. Primary endpoint: Acne lesion count at week 16. Started Aug 2008; status: completed.
02
Drugs
isotretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ACTRN12612000062820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000062820.